A comprehensive review on the lipid and pleiotropic effects of pitavastatin.

[1]  M. Banach,et al.  Effects of statins on mitochondrial pathways , 2021, Journal of cachexia, sarcopenia and muscle.

[2]  Xiao-lin Li,et al.  Effects of Pitavastatin on Lipoprotein Subfractions and Oxidized Low-density Lipoprotein in Patients with Atherosclerosis , 2020, Current Medical Science.

[3]  K. Seung,et al.  Efficacy and Tolerability of Pitavastatin Versus Pitavastatin/Fenofibrate in High-risk Korean Patients with Mixed Dyslipidemia: A Multicenter, Randomized, Double-blinded, Parallel, Therapeutic Confirmatory Clinical Trial. , 2020, Clinical therapeutics.

[4]  T. Kitazono,et al.  Simultaneous targeting of mitochondria and monocytes enhances neuroprotection against ischemia–reperfusion injury , 2020, Scientific Reports.

[5]  A. Sahebkar,et al.  Effects of statins on brain tumors: a review. , 2020, Seminars in cancer biology.

[6]  N. Kiaie,et al.  Antiviral effects of statins. , 2020, Progress in lipid research.

[7]  R. Krishnan,et al.  Inhibiting Airway Smooth Muscle Contraction Using Pitavastatin: A Role for the Mevalonate Pathway in Regulating Cytoskeletal Proteins , 2020, Frontiers in Pharmacology.

[8]  R. Krishnan,et al.  Anti-Inflammatory Effects of Pitavastatin in Human Airway Structural Cells Occur by a GGPP-Dependent Mechanism , 2020 .

[9]  M. Banach,et al.  What do we know about the role of lipoprotein(a) in atherogenesis 57 years after its discovery? , 2020, Progress in cardiovascular diseases.

[10]  W. Tian,et al.  Effects of nanoparticle-mediated delivery of pitavastatin on atherosclerotic plaques in ApoE-knockout mice and THP-1-derived macrophages , 2020, Experimental and therapeutic medicine.

[11]  P. Devreotes,et al.  Statin-induced GGPP depletion blocks macropinocytosis and starves cells with oncogenic defects , 2020, Proceedings of the National Academy of Sciences.

[12]  N. Kiaie,et al.  Effects of statins on the biological features of mesenchymal stem cells and therapeutic implications , 2020, Heart Failure Reviews.

[13]  Guofang Zhao,et al.  Cholesterol-lowering drug pitavastatin targets lung cancer and angiogenesis via suppressing prenylation-dependent Ras/Raf/MEK and PI3K/Akt/mTOR signaling , 2020, Anti-cancer drugs.

[14]  S. Bo,et al.  Effects of 3-hydroxy-3-methylglutaryl coenzyme A reductase inhibitors on ageing: Molecular mechanisms , 2020, Ageing Research Reviews.

[15]  M. Moroi,et al.  Outcome of pitavastatin versus atorvastatin therapy in patients with hypercholesterolemia at high risk for atherosclerotic cardiovascular disease. , 2020, International journal of cardiology.

[16]  M. Banach,et al.  Statins and Lp(a): do not make perfect the enemy of excellent. , 2019, European heart journal.

[17]  Steven P Jones,et al.  Modern prevalence of dysbetalipoproteinemia (Fredrickson-Levy-Lees type III hyperlipoproteinemia) , 2019, Archives of medical science : AMS.

[18]  James M. Wright,et al.  Pitavastatin for lowering lipids. , 2017, The Cochrane database of systematic reviews.

[19]  F. Mücklich,et al.  Injectable calcium phosphate foams for the delivery of Pitavastatin as osteogenic and angiogenic agent. , 2020, Journal of biomedical materials research. Part B, Applied biomaterials.

[20]  T. Sathyapalan,et al.  The effects of statins on microglial cells to protect against neurodegenerative disorders: A mechanistic review , 2019, BioFactors.

[21]  M. Banach,et al.  Statin-Induced Nitric Oxide Signaling: Mechanisms and Therapeutic Implications , 2019, Journal of clinical medicine.

[22]  Amanda P. Siegel,et al.  Pitavastatin slows tumor progression and alters urine‐derived volatile organic compounds through the mevalonate pathway , 2019, FASEB journal : official publication of the Federation of American Societies for Experimental Biology.

[23]  P. Joshi,et al.  Characterization of lipoprotein profiles in patients with hypertriglyceridemic Fredrickson-Levy and Lees dyslipidemia phenotypes: the Very Large Database of Lipids Studies 6 and 7 , 2019, Archives of medical science : AMS.

[24]  F. Khanim,et al.  Screening a library of approved drugs reveals that prednisolone synergizes with pitavastatin to induce ovarian cancer cell death , 2019, Scientific Reports.

[25]  Sy-Jou Chen,et al.  Pitavastatin Exerts Potent Anti-Inflammatory and Immunomodulatory Effects via the Suppression of AP-1 Signal Transduction in Human T Cells , 2019, International journal of molecular sciences.

[26]  P. Joshi,et al.  Comparing different assessments of remnant lipoprotein cholesterol: The very large database of lipids. , 2019, Journal of clinical lipidology.

[27]  A. Akkan,et al.  The Effects of Pitavastatin on Nuclear Factor-Kappa B and ICAM-1 in Human Saphenous Vein Graft Endothelial Culture , 2019, Cardiovascular therapeutics.

[28]  Takahiro Miura,et al.  Pitavastatin Upregulates Nitric Oxide Synthases in the Kidney of Spontaneously Hypertensive Rats and Wistar–Kyoto Rats , 2018, American journal of hypertension.

[29]  Y. Ohashi,et al.  High-Dose Versus Low-Dose Pitavastatin in Japanese Patients With Stable Coronary Artery Disease (REAL-CAD) , 2018, Circulation.

[30]  P. Giral,et al.  Duality of statin action on lipoprotein subpopulations in the mixed dyslipidemia of metabolic syndrome: Quantity vs quality over time and implication of CETP. , 2018, Journal of clinical lipidology.

[31]  A. Imai.  Efficacy and Safety of Pitavastatin in Menopausal Women with Dyslipidemia , 2018 .

[32]  Xiaofei Nan,et al.  Pitavastatin treatment induces neuroprotection through the BDNF-TrkB signalling pathway in cultured cerebral neurons after oxygen-glucose deprivation , 2018, Neurological research.

[33]  M. Mazidi,et al.  Higher dietary acid load is associated with higher likelihood of peripheral arterial disease among American adults. , 2018, Journal of diabetes and its complications.

[34]  A. Sahebkar,et al.  Improvement of endothelial function by pitavastatin: a meta-analysis , 2018, Expert opinion on pharmacotherapy.

[35]  T. Mitsuhashi,et al.  Endothelial Nitric Oxide Synthase-Independent Pleiotropic Effects of Pitavastatin Against Atherogenesis and Limb Ischemia in Mice , 2018, Journal of atherosclerosis and thrombosis.

[36]  Zhiming Du,et al.  Pitavastatin attenuates atherosclerosis by suppressing NF-κB signaling in a high-cholesterol diet plus balloon catheter injury rabbit model. , 2018, International journal of clinical and experimental pathology.

[37]  Xiaohui Zhao,et al.  Pitavastatin nanoparticle-engineered endothelial progenitor cells repair injured vessels , 2017, Scientific Reports.

[38]  F. Ahmad,et al.  Intranasal pitavastatin attenuates seizures in different experimental models of epilepsy in mice , 2017, Epilepsy & Behavior.

[39]  M. Banach,et al.  Optimizing Cholesterol Treatment in Patients With Muscle Complaints. , 2017, Journal of the American College of Cardiology.

[40]  Hai-Jie Yang,et al.  Anti‐inflammatory effects of pitavastatin in interleukin‐1&bgr;‐induced SW982 human synovial cells , 2017, International immunopharmacology.

[41]  Songquan Wu,et al.  Anti-asthmatic effect of pitavastatin through aerosol inhalation is associated with CD4+ CD25+ Foxp3+ T cells in an asthma mouse model , 2017, Scientific Reports.

[42]  Dietary geranylgeraniol can limit the activity of pitavastatin as a potential treatment for drug-resistant ovarian cancer , 2017, Scientific Reports.

[43]  A. Catapano,et al.  Pitavastatin and HDL: Effects on plasma levels and function(s). , 2017, Atherosclerosis. Supplements.

[44]  D. Ward,et al.  Pitavastatin versus pravastatin in adults with HIV-1 infection and dyslipidaemia (INTREPID): 12 week and 52 week results of a phase 4, multicentre, randomised, double-blind, superiority trial. , 2017, The lancet. HIV.

[45]  M. Jeong,et al.  Efficacy and safety of pitavastatins in patients with acute myocardial infarction: Livalo in Acute Myocardial Infarction Study (LAMIS) II , 2017, The Korean journal of internal medicine.

[46]  M. Mohammadi,et al.  Anticonvulsant and Antioxidant Effects of Pitavastatin Against Pentylenetetrazol-Induced Kindling in Mice , 2017, Advanced pharmaceutical bulletin.

[47]  K. Shimada,et al.  Effects of pitavastatin on walking capacity and CD34+/133+ cell number in patients with peripheral artery disease , 2017, Heart and Vessels.

[48]  R. D'Agostino,et al.  Greater remnant lipoprotein cholesterol reduction with pitavastatin compared with pravastatin in HIV-infected patients , 2017, AIDS (London).

[49]  Kenneth C. Williams,et al.  Effects of pitavastatin and pravastatin on markers of immune activation and arterial inflammation in HIV , 2017, AIDS.

[50]  Wenjun Wu,et al.  Effects of Pitavastatin on Lipid-rich Carotid Plaques Studied Using High-resolution Magnetic Resonance Imaging. , 2017, Clinical therapeutics.

[51]  Shiya Zheng,et al.  Targeting colon cancer stem cells with novel blood cholesterol drug pitavastatin. , 2017, European review for medical and pharmacological sciences.

[52]  Jingmin Zhao,et al.  Pitavastatin inhibits proinflammatory cytokines and provides improvement in terms of its motor function in secondary injuries of the spinal cord mouse models , 2017 .

[53]  B. Nordestgaard,et al.  Remnant lipoproteins. , 2017, Current opinion in lipidology.

[54]  M. Pencina,et al.  Impact of statin therapy on plasma adiponectin concentrations: A systematic review and meta-analysis of 43 randomized controlled trial arms. , 2016, Atherosclerosis.

[55]  H. You,et al.  Pitavastatin suppressed liver cancer cells in vitro and in vivo , 2016, OncoTargets and therapy.

[56]  M. Banach,et al.  Molecular mechanisms of statin intolerance , 2016, Archives of medical science : AMS.

[57]  R. D'Agostino,et al.  Pitavastatin 4 mg Provides Significantly Greater Reduction in Remnant Lipoprotein Cholesterol Compared With Pravastatin 40 mg: Results from the Short-term Phase IV PREVAIL US Trial in Patients With Primary Hyperlipidemia or Mixed Dyslipidemia. , 2016, Clinical therapeutics.

[58]  C. Jung,et al.  Effect of Pitavastatin Treatment on ApoB-48 and Lp-PLA2 in Patients with Metabolic Syndrome: Substudy of PROspective Comparative Clinical Study Evaluating the Efficacy and Safety of PITavastatin in Patients with Metabolic Syndrome , 2016, Endocrinology and metabolism.

[59]  B. R. Hsu,et al.  Pitavastatin improves glycated hemoglobin in patients with poorly controlled type 2 diabetes , 2016, Journal of diabetes investigation.

[60]  A. Hirayama,et al.  Stabilization of atherosclerotic plaque by pitavastatin in Watanabe heritable hyperlipidemic rabbits: A serial tissue-characterizing intravascular ultrasound study. , 2016, Journal of cardiology.

[61]  A. Sahebkar,et al.  The impact of statin therapy on plasma levels of von Willebrand factor antigen , 2015, Thrombosis and Haemostasis.

[62]  Qiang Zhou,et al.  Pitavastatin attenuates monocyte activation in response to orthopedic implant-derived wear particles by suppressing the NF-κB signaling pathway. , 2015, Molecular medicine reports.

[63]  A. Sahebkar,et al.  Effect of statin therapy on paraoxonase-1 status: A systematic review and meta-analysis of 25 clinical trials. , 2015, Progress in lipid research.

[64]  Jose-Luiz Figueiredo,et al.  Pitavastatin Reduces Inflammation in Atherosclerotic Plaques in Apolipoprotein E-Deficient Mice with Late Stage Renal Disease , 2015, PloS one.

[65]  M. Banach,et al.  Association between statin use and plasma d-dimer levels – A systematic review and meta-analysis of randomized controlled trials , 2015 .

[66]  A. Sahebkar,et al.  A systematic review and meta-analysis of the effect of statins on plasma asymmetric dimethylarginine concentrations , 2015, Scientific Reports.

[67]  Jing Zhao,et al.  Pitavastatin calcium improves endothelial function and delays the progress of atherosclerosis in patients with hypercholesterolemia , 2015, Journal of Zhejiang University-SCIENCE B.

[68]  Chih-Zen Chang,et al.  Preconditioning with pitavastatin, an HMG-CoA reductase inhibitor, attenuates C-Jun N-terminal kinase activation in experimental subarachnoid hemorrhage-induced apoptosis , 2015, Acta Neurochirurgica.

[69]  W. Baker,et al.  Benefit–risk assessment of pitavastatin for the treatment of hypercholesterolemia in older patients , 2015, Clinical interventions in aging.

[70]  M. Arai,et al.  Anti-inflammatory and morphologic effects of pitavastatin on carotid arteries and thoracic aorta evaluated by integrated backscatter trans-esophageal ultrasound and PET/CT: a prospective randomized comparative study with pravastatin (EPICENTRE study) , 2015, Cardiovascular Ultrasound.

[71]  M. Banach,et al.  Statin intolerance – an attempt at a unified definition. Position paper from an International Lipid Expert Panel , 2015, Expert opinion on drug safety.

[72]  N. Hagiwara,et al.  Effects of Statin versus the Combination of Ezetimibe plus Statin on Serum Lipid Absorption Markers in Patients with Acute Coronary Syndrome , 2015, Journal of lipids.

[73]  M. Adamkov,et al.  Combination of Pitavastatin and melatonin shows partial antineoplastic effects in a rat breast carcinoma model. , 2014, Acta histochemica.

[74]  S. Pastorino,et al.  In vitro and in vivo anticancer effects of mevalonate pathway modulation on human cancer cells , 2014, British Journal of Cancer.

[75]  M. Davidson,et al.  Comparison of the lipid-lowering effects of pitavastatin 4 mg versus pravastatin 40 mg in adults with primary hyperlipidemia or mixed (combined) dyslipidemia: a Phase IV, prospective, US, multicenter, randomized, double-blind, superiority trial. , 2014, Clinical therapeutics.

[76]  Liang-Yu Lin,et al.  Effects of pitavastatin versus atorvastatin on the peripheral endothelial progenitor cells and vascular endothelial growth factor in high-risk patients: a pilot prospective, double-blind, randomized study , 2014, Cardiovascular Diabetology.

[77]  N. Takekoshi,et al.  Comparison of atorvastatin, pitavastatin and rosuvastatin for residual cardiovascular risk using non-fasting blood sampling , 2014, Scandinavian journal of clinical and laboratory investigation.

[78]  T. Horio,et al.  Comparison of Efficacy of Intensive versus Mild Pitavastatin Therapy on Lipid and Inflammation Biomarkers in Hypertensive Patients with Dyslipidemia , 2014, PloS one.

[79]  Statins and Neuroprotection: Basic Pharmacology Needed , 2014, Molecular Neurobiology.

[80]  Taher Abbasi,et al.  Novel anti-glioblastoma agents and therapeutic combinations identified from a collection of FDA approved drugs , 2014, Journal of Translational Medicine.

[81]  K. Chien,et al.  Pitavastatin and Atorvastatin Double-Blind Randomized ComPArative Study among HiGh-Risk Patients, Including ThOse with Type 2 Diabetes Mellitus, in Taiwan (PAPAGO-T Study) , 2013, PloS one.

[82]  M. Banach,et al.  Rationale of statin therapy in septic patients. , 2013, Current vascular pharmacology.

[83]  K. Sakamoto,et al.  Comparison of pitavastatin with atorvastatin in increasing HDL-cholesterol and adiponectin in patients with dyslipidemia and coronary artery disease: the COMPACT-CAD study. , 2013, Journal of cardiology.

[84]  N. Hayashi,et al.  Pitavastatin ameliorated the progression of steatohepatitis in ovariectomized mice fed a high fat and high cholesterol diet , 2013, Hepatology research : the official journal of the Japan Society of Hepatology.

[85]  K. Hirata,et al.  PITAVASTATIN INCREASES HDL PARTICLES WITH PRESERVED ANTI–ATHEROSCLEROTIC PROPERTIES IN DYSLIPIDEMIC PATIENTS , 2013 .

[86]  K. Abe,et al.  Atorvastatin and pitavastatin reduce oxidative stress and improve IR/LDL-R signals in Alzheimer’s disease , 2013, Neurological research.

[87]  M. Gosho,et al.  Pitavastatin shows greater lipid-lowering efficacy over 12 weeks than pravastatin in elderly patients with primary hypercholesterolaemia or combined (mixed) dyslipidaemia , 2013, European journal of preventive cardiology.

[88]  J. Witztum,et al.  Effects of pitavastatin and atorvastatin on lipoprotein oxidation biomarkers in patients with dyslipidemia. , 2013, Atherosclerosis.

[89]  K. Hirata,et al.  Pitavastatin increases HDL particles functionally preserved with cholesterol efflux capacity and antioxidative actions in dyslipidemic patients. , 2013, Journal of atherosclerosis and thrombosis.

[90]  M. Banach,et al.  Dysfunctional HDL: a novel important diagnostic and therapeutic target in cardiovascular disease? , 2012, Progress in lipid research.

[91]  K. Abe,et al.  Atorvastatin and pitavastatin reduce senile plaques and inflammatory responses in a mouse model of Alzheimer’s disease , 2012, Neurological research.

[92]  Khayatnouri Mirhadi.  Anticonvulsant Effect of Pitavastatin in Mice Induced by Pentylenetetrazole , 2012 .

[93]  B. Zhang,et al.  Statins Induce the Gene Expression of Apolipoprotein A5 in HepG2 Cells , 2011 .

[94]  K. Abe,et al.  Progressive neurovascular disturbances in the cerebral cortex of Alzheimer's disease-model mice: protection by atorvastatin and pitavastatin , 2011, Neuroscience.

[95]  J. Gumprecht,et al.  Comparative long‐term efficacy and tolerability of pitavastatin 4 mg and atorvastatin 20–40 mg in patients with type 2 diabetes mellitus and combined (mixed) dyslipidaemia , 2011, Diabetes, obesity & metabolism.

[96]  Y. Saito,et al.  Pitavastatin: an overview. , 2011, Atherosclerosis. Supplements.

[97]  Y. Matsuzaki,et al.  Efficacy of pitavastatin for the treatment of non‐alcoholic steatohepatitis with dyslipidemia: An open‐label, pilot study , 2011, Hepatology research : the official journal of the Japan Society of Hepatology.

[98]  M. Eriksson,et al.  Comparative efficacy of pitavastatin and simvastatin in high-risk patients: a randomized controlled trial , 2011, Advances in therapy.

[99]  Shigeki Masuda,et al.  Comparison of preventive effect on cardiovascular events with different statins. -The CIRCLE study-. , 2011, Circulation journal : official journal of the Japanese Circulation Society.

[100]  B. Zhang,et al.  Randomized head-to-head comparison of pitavastatin, atorvastatin, and rosuvastatin for safety and efficacy (quantity and quality of LDL): the PATROL trial. , 2011, Circulation journal : official journal of the Japanese Circulation Society.

[101]  K. Matsuura,et al.  Pitavastatin inhibits hepatic steatosis and fibrosis in non‐alcoholic steatohepatitis model rats , 2011, Hepatology research : the official journal of the Japan Society of Hepatology.

[102]  T. Murohara,et al.  Pitavastatin-induced angiogenesis and arteriogenesis is mediated by Notch1 in a murine hindlimb ischemia model without induction of VEGF , 2011, Laboratory Investigation.

[103]  K. Abe,et al.  Atorvastatin and pitavastatin improve cognitive function and reduce senile plaque and phosphorylated tau in aged APP mice , 2011, Brain Research.

[104]  T. Teramoto.  A Large－Scale Survey on Cardio－Cerebrovascular EventsDuring Pitavastatin（LIVALO Tablet）Therapyin Japanese Patients with Hypercholesterolemia―LIVALO Effectiveness and Safety Study Extension（LIVES Study Extension）― , 2011 .

[105]  M. Eriksson,et al.  MS389 PITAVASTATIN 4 mg SHOWS COMPARABLE LDL-CHOLESTEROL AND SUPERIOR TRIGLYCERIDE REDUCTION TO SIMVASTATIN 40 mg IN HIGH-RISK PRIMARY HYPERCHOLESTEROLEMIA OR COMBINED DYSLIPIDEMIA , 2010 .

[106]  N. Hounslow,et al.  Long-term treatment with pitavastatin is effective and well tolerated by patients with primary hypercholesterolemia or combined dyslipidemia. , 2010, Atherosclerosis.

[107]  M. Urashima,et al.  Effects of pitavastatin (LIVALO Tablet) on high density lipoprotein cholesterol (HDL-C) in hypercholesterolemia. , 2009, Journal of atherosclerosis and thrombosis.

[108]  N. Hounslow,et al.  Comparison of pitavastatin with simvastatin in primary hypercholesterolaemia or combined dyslipidaemia , 2009, Current medical research and opinion.

[109]  H. Ohbayashi,et al.  Pitavastatin improves plasma pentraxin 3 and arterial stiffness in atherosclerotic patients with hypercholesterolemia. , 2009, Journal of atherosclerosis and thrombosis.

[110]  Katsumi Miyauchi,et al.  Effect of intensive statin therapy on regression of coronary atherosclerosis in patients with acute coronary syndrome: a multicenter randomized trial evaluated by volumetric intravascular ultrasound using pitavastatin versus atorvastatin (JAPAN-ACS [Japan assessment of pitavastatin and atorvastatin , 2009, Journal of the American College of Cardiology.

[111]  K. Sunagawa,et al.  Therapeutic Neovascularization by Nanotechnology-Mediated Cell-Selective Delivery of Pitavastatin Into the Vascular Endothelium , 2009, Arteriosclerosis, thrombosis, and vascular biology.

[112]  N. Hounslow,et al.  Pitavastatin compared with atorvastatin in primary hypercholesterolemia or combined dyslipidemia , 2009 .

[113]  E. Mannarino,et al.  Influence of Short-term Rosuvastatin Therapy on Endothelial Progenitor Cells and Endothelial Function , 2009, Journal of cardiovascular pharmacology and therapeutics.

[114]  T. Kodama,et al.  Multicenter collaborative randomized parallel group comparative study of pitavastatin and atorvastatin in Japanese hypercholesterolemic patients: collaborative study on hypercholesterolemia drug intervention and their benefits for atherosclerosis prevention (CHIBA study). , 2008, Atherosclerosis.

[115]  K. Hirata,et al.  Effects of pitavastatin on lipid profiles and high-sensitivity CRP in Japanese subjects with hypercholesterolemia: Kansai Investigation of Statin for Hyperlipidemic Intervention in Metabolism and Endocrinology (KISHIMEN) investigatars. , 2008, Journal of atherosclerosis and thrombosis.

[116]  J. Sasaki,et al.  A 52-week, randomized, open-label, parallel-group comparison of the tolerability and effects of pitavastatin and atorvastatin on high-density lipoprotein cholesterol levels and glucose metabolism in Japanese patients with elevated levels of low-density lipoprotein cholesterol and glucose intolerance , 2008, Clinical therapeutics.

[117]  T. Fujii,et al.  Statins restore ischemic limb blood flow in diabetic microangiopathy via eNOS/NO upregulation but not via PDGF-BB expression Authors: , 2008 .

[118]  T. Douzono,et al.  A Large-scale, Long-term, Prospective Post-marketing Surveillance of Pitavastatin (LIVALO®Tablet) : LIVALO Effectiveness and Safety (LIVES) Study , 2008 .

[119]  I. Wilkinson,et al.  Ezetimibe and simvastatin reduce inflammation, disease activity, and aortic stiffness and improve endothelial function in rheumatoid arthritis. , 2007, Journal of the American College of Cardiology.

[120]  H. Otani,et al.  Renal protective effects of pitavastatin on spontaneously hypercholesterolaemic Imai Rats. , 2007, Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association.

[121]  Takuji Tanaka,et al.  A lipophilic statin, pitavastatin inhibits inflammation-associated mouse colon carcinogenesis , 2007 .

[122]  T. Nakazawa,et al.  Pitavastatin prevents NMDA‐induced retinal ganglion cell death by suppressing leukocyte recruitment , 2007, Journal of neurochemistry.

[123]  M. Inatani,et al.  Pitavastatin: Protection against Neuronal Retinal Damage Induced by Ischemia-Reperfusion Injury in Rats , 2007, Current eye research.

[124]  R. Paltriccia,et al.  Increased Ratio of CD31+/CD42− Microparticles to Endothelial Progenitors as a Novel Marker of Atherosclerosis in Hypercholesterolemia , 2006, Arteriosclerosis, thrombosis, and vascular biology.

[125]  Y. Ikeda,et al.  Effect of pitavastatin on transactivation of human serum paraoxonase 1 gene. , 2005, Metabolism: clinical and experimental.

[126]  E. Mannarino,et al.  Paraoxonase-1 activity modulates endothelial function in patients with peripheral arterial disease. , 2005, Atherosclerosis.

[127]  L. Ignarro,et al.  A new HMG-CoA reductase inhibitor, pitavastatin remarkably retards the progression of high cholesterol induced atherosclerosis in rabbits. , 2004, Atherosclerosis.

[128]  M. Imamura,et al.  Pitavastatin enhances the anti-fibrogenesis effects of candesartan, an angiotensin II receptor blocker, on CCl4-induced liver fibrosis in rats. , 2004, Journal of UOEH.

[129]  H. Kato,et al.  Pitavastatin, a 3-hydroxy-3-methylglutaryl-coenzyme A (HMG-CoA) reductase inhibitor, reduces hippocampal damage after transient cerebral ischemia in gerbils , 2004, Journal of Neural Transmission.

[130]  G. Ciuffetti,et al.  Mechanisms of high-density lipoprotein cholesterol effects on the endothelial function in hyperlipemia. , 2003, Metabolism: clinical and experimental.